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Background:Neuromyelitis optica (NMO) is an inﬂammatory disease of the central nervous system that predom-
inantly affects the optic nerves and spinal cord. Although NMO has long been considered a subtype of multiple
sclerosis (MS), the effects of interferon-β treatment are different between NMO and MS. Recent ﬁndings of
NMO-IgG suggest that NMO could be a distinct disease rather than a subtype ofMS. However, the underlyingmo-
lecular mechanism of NMO pathology remains poorly understood.
Methods:OPN in the cerebrospinal ﬂuid and brain of patients with NMO and with MS, as well as of patients with
other neurologic disease/idiopathic other neurologic disease was examined using Western blotting, ELISA, im-
munohistochemistry and Boyden chamber.
Results:Herewe show that osteopontin is signiﬁcantly increased in the cerebrospinal ﬂuid of NMOpatients com-
paredwithMS patients. Immunohistochemical analyses revealed that osteopontinwasmarkedly elevated in the
cerebral white matter of NMO patients and produced by astrocytes, neurons, and oligodendroglia as well as in-
ﬁltrating macrophages. We also demonstrate that the interaction of the cerebrospinal ﬂuid osteopontin in
NMO patients with integrin αvβ3 promoted macrophage chemotaxis by activating phosphoinositide 3-kinase
and MEK1/2 signaling pathways.
Conclusion: These results indicate that osteopontin is involved in NMO pathology.
General signiﬁcance: Thus therapeutic strategies that target osteopontin signaling may be useful to treat NMO.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neuromyelitis optica (NMO) is an inﬂammatory demyelinating dis-
ease of the central nervous system (CNS) that primarily affects the optic
nerves and spinal cord leading to paralysis and blindness [28]. NMO has
long been considered a subtype of multiple sclerosis (MS), which is
characterized by myelin breakdown, oligodendrocyte loss, and axonaluaporin-4; CNS, central nervous
toimmune encephalomyelitis;
noclonalantibody;MS,multiple
pAb, polyclonal antibody; PI3K,
Arg–Gly–Glu; TRAP, tartrate-
emistry, Fukushima Medical
960-1295, Japan. Tel.: +81 24
fmu.ac.jp (Y. Hashimoto).
. This is an open access article underdamage [8,12]. However, the attacks of NMO are usually more severe
than those of MS, and spinal cord magnetic resonance imaging (MRI)
can aid in the diagnosis [28]. The recent discovery of NMO-IgG in the
serum of a high percentage of NMO patients (~75%) that are usually ab-
sent in the conventional form of MS, and the subsequent identiﬁcation
of its target antigen, aquaporin-4 (AQP4), which is the most abundant
water channel at the astrocyte endfeet in CNS, provided strong evidence
that NMOwas distinct fromMS [17]. The NMOphenotype can be attrib-
uted toNMO-IgG and complement attacking astrocytes in the nerve and
spinal cord. In demyelinated active lesions of NMO patients, extensive
macrophage inﬁltration associated with large numbers of perivascular
granulocytes and eosinophils and rare T cells was observed [10,18].
While it remains unclear how these inﬂammatory or immune cells are
involved inNMOpathogenesis, these ﬁndings indicate that themost ap-
propriate treatment may differ for NMO andMS. In fact, several case re-
ports have shown the contrasting effects of interferon (IFN)-β
treatment; inNMO, IFN-β induces severe relapses and exacerbations, al-
though it is the most commonly prescribed treatment for relapsingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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disorders to select optimal treatment.
Osteopontin (OPN) is involved in various physiological and patho-
logical events, including mineralization, acute and chronic inﬂamma-
tion, and cancer metastasis [15,22,23]. OPN is believed to play an
important role in several autoimmune diseases such asMS [6], rheuma-
toid arthritis [30], systemic lupus erythematosus [13], and asthma [29].
In relapsing remitting MS, increased OPN protein levels in the plasma
but not in the cerebrospinal ﬂuid (CSF) are associated with disease
activity [24,25]. It has also been reported that OPN concentrations are
increased in CSF during attacks of MS [4]. OPN expression is elevated
in the CNS lesions of experimental autoimmune encephalomyelitis
(EAE) during the acute phase but not during remission, and OPN plays
a critical role in EAE progression [6].
Osteopontin (OPN) is amultiphosphorylated extracellular glycopro-
tein. The molecular weight of OPN on SDS-PAGE varies from 45 to
75 kDa due to glycosylation and phosphorylation as well as having a
highly negative charge resulting from the predominantly acidic amino
acid composition [15]. OPN contains an Arg–Gly–Asp (RGD) sequence
common to many extracellular matrix proteins, which mediate the
association of OPN with multiple integrins such as α5β1, αvβ1, and
αvβ3 [14,15,23]. Another important receptor for OPN is CD44, and
thrombin-cleaved carboxyl-terminal OPN fragments bind to CD44 vari-
ants in an RGD-independent manner [3]. The binding of OPN to these
cell surface receptors induces cellular signaling pathways such as
phosphoinositide 3-kinase (PI3K), MAPK, and JNK to regulate various
cell functions, including adhesion, migration, chemotaxis, and prolifera-
tion in various types of cells [3,14,23].
In this study,we found that OPNwas signiﬁcantly increased in CSF of
patients with NMO compared with patients with MS or other diseases.
Immunohistochemical analyses using anti-OPN antibody (Ab) showed
the aberrant expression of OPN in the cerebral white matter of the
NMO patients. Of note, OPN in CSF of NMO patients was found to be a
primary protein that promptly induced macrophage chemotaxis.
2. Materials and methods
2.1. Compliance with ethical standards for human subject research
Study approval (number 613) was granted after protocol review by
the Ethics Committee of FukushimaMedical University, which is guided
by local policy, national law, and the World Medical Association Decla-
ration of Helsinki.
2.2. CSF, serum, and plasma samples
CSF samples were obtained at the time of relapse from anti-AQP4
Ab-positive NMO patients (n = 19; all females; mean age, 47.4 ± 14.7
years), and MS patients (n = 19; one male and 18 females; mean age,
34.4 ± 10.8 years). The mean times from symptom onset to lumbar
puncture were 5.5 days (range: 0–17 days) for NMO and 13.4 days
(range: 2–56 days) for MS. The mean disease durations were 5.2 ±
10.8 years (range: 25 days–46 years) for NMO and 4.6 ± 8.0 years
(range: 19 days–36 years) for MS. Fourteen patients with other neuro-
logic disease/idiopathic other neurologic disease (OND/IOND) (1 sacro-
iliac joint dysfunction; 1 Parkinson's disease; 1 cervical spondylosis; 1
spinocerebellar ataxia type 6; 1 multiple system atrophy-P; 1 sarcoido-
sis; 1 HTLV-1-associated myelopathy; 1 subterranean clover stunt dis-
ease; and 3 NMDAR Ab-negative and 3 NMDAR Ab-positive limbic
encephalitis; two males and 12 females: mean age, 47.7 ± 19.1 years)
served as disease controls. The mean disease duration was 4.5 ±
6.7 years (range: 26 days–23 years) for the control group. The age at
onset was higher in NMO than in MS (p b 0.05) while in control it did
not differ signiﬁcantly in NMO (NMO vs. control) and inMS (MS vs. con-
trol). The disease durations did not differ signiﬁcantly among the three.
After obtaining informed consent from the patients, the CSF sampleswere obtained by lumbar puncture and then centrifuged to remove
cells and other insoluble materials. The cell-free CSF supernatant was
aliquoted in tubes and stored at−80 °C until use. Blood samples collect-
ed from patients were either heparinized and directly centrifuged at
1000 g for 10 min at room temperature to obtain plasma or allowed to
clot at 4 °C overnight before centrifugation, after which serum was
transferred and stored at−80 °C until use.2.3. Abs and reagents
Rabbit polyclonal Abs (pAbs) were usedwith the following speciﬁc-
ities: against human OPN (O-17; IBL, Cat# 18625), and against Akt (Cell
Signaling, Cat# 9272). Mouse monoclonal Abs (mAbs) were used with
the following speciﬁcities: against OPN (clone 53; Assay Designs, Cat#
905–629 or clone 10A16; IBL, Cat# 10011), against integrin αvβ3
(clone LM609; Millipore, Cat# MAB1976), against phospho-p44/42
MAPK (clone E10; Cell Signaling, Cat# 9106S), against CNPase (clone
11-5B; GeneTex, Cat# GTX72341), and against ERK1 (clone MK12;
Cat# 610031), JNK/SAPK1 (clone 37/pan-JNK/SAPK1; Cat# 610627),
phospho-JNK/SAPK [pT183/pY185, clone 41/JNK/SAPK (pT183/
pY185); Cat# 612540], p38α (clone 27/p38α/SAPK2a; Cat# 612168),
and phospho-p38 MAPK [pT180/pY182, clone 30/p38 MAPK (pT180/
pY182); Cat# 612280] from BD Transduction laboratories. A rat mAb
against CD44 (clone Hermes-1; Cat#MA4400)was fromThermo Scien-
tiﬁc. Rabbit mAbs against phospho-Akt1 (pS473, clone EP2109Y;
Cat #2118-1), and against glial ﬁbrillary acidic protein (GFAP; clone
EPR1034Y; Cat #2301-1) were from Epitomics. The control rat
(Cat# sc-2026), and mouse (Cat# sc-2025) IgGs, and a mouse mAb
against integrin αvβ3 (clone 23C6; Cat# sc-7312) for FACS analysis
were obtained from Santa Cruz Biotechnology, Inc.; Alexa Fluor 488-
conjugated goat anti-rabbit IgG (Cat# A11008) and Alexa Fluor 546-
conjugated goat anti-mouse IgG (Cat# A11030) were purchased from
Life Technologies. The PI3K inhibitor LY294002 (Cat# 70920) was from
Cayman Chemical, and the MEK1/2 inhibitor U0126 (Cat# 662005),
the JNK inhibitor SP600125 (Cat# 420119), and the p38MAPK inhibitor
SB203580 (Cat# 559389)were fromCalbiochem. GRGDSP (Cat# SP001)
and GRGESP (Cat# SP002) peptides were from Takara Bio Inc., and calf
intestine alkaline phosphatase (CIAP; Cat# CAP-101) was purchased
from Toyobo. Recombinant OPN was puriﬁed from human wild-type
OPN overexpressing 293T cells as described previously [14].2.4. SDS-PAGE and Western blot
SDS-PAGE was performed on 5–20% SuperSep™ Ace gradient gels
(Wako, Cat# 194-15021) under reducing conditions. For Western blot
analyses, proteins resolved by SDS-PAGEwere transferred to nitrocellu-
losemembranes. The blotswere probedwith each speciﬁc Ab. Immuno-
reactive bands were detected using a SuperSignal West Dura Extended
Duration Substrate kit (Thermo Scientiﬁc, Cat# 34075). The band inten-
sity was calculated using NIH ImageJ software.2.5. ELISA assay
OPN levels in CSF samples weremeasured using a human osteopon-
tin ELISA kit (R&D systems, Cat# DOST00), according to the
manufacturer's protocols.2.6. Dephosphorylation of CSF and serum samples
CSF and serum samples were boiled for 5 min at 95 °C, followed by
incubation for 1 h at 37 °C in the presence of 3 units of puriﬁed CIAP
in 10 mM Tris–HCl (pH 8.0) buffer.
Fig. 1. Increased OPN levels in CSF of NMO patients. (A) CSF samples (1 μl) from independent patients with diseases as indicated were applied to SDS-PAGE under reducing conditions,
followed byWestern blot using anti-humanOPN pAb. Other diseases (others): sacroiliac joint dysfunction (lane 13) and Parkinson disease (PD) (lane 14). Other procedures are described
in Materials and Methods. rOPN, recombinant OPN, for which phosphorylation level is very low, for positive control. The arrowhead indicates the corresponding band in Fig. 1B. (B) The
same quantity of protein (3 μg) in the indicated CSF samples from independent patients was loaded to SDS-PAGE under reducing conditions, followed byWestern blot using anti-human
OPN pAb. Other diseases (others) include sacroiliac joint dysfunction (lane 10), PD (lane 11), cervical spondylosis (lane 12), and spinocerebellar ataxia type 6 (lane 13). The samples in
lanes 1–4, 5–9 and 10–11 in Fig. 1B were identical to the samples in lanes 1–4, 7–11, and 13–14 in Fig. 1A, respectively. Vertical line indicates the removal of an intervening lane for pre-
sentation purposes. (C) Concentration of OPN in each CSF sample wasmeasured by ELISA. Each point in the scatter plot represents mean OPN concentration of experiments conducted in
duplicate. The horizontal lines represent themedian of each patient group. Patients with NMO (n= 19) had signiﬁcantly elevated OPN protein levels compared with thosewithMS (n=
19) and other diseases (others, n= 14).We used a Kruskal–Wallis test followed by Dunn's post-test to assess differences. The intra assay coefﬁcient of variation (% CV)was lower than 9%
(almost always less than 2%). (D)Western blot analysis of OPN in the serum of NMO (lanes 1–3) andMS (lanes 4–7) patients. Each 1 μl of serum samples diluted 1:10 in PBSwas run on a
5–20% SDS-PAGE gel under reducing conditions, followed byWestern blot using anti-human OPN pAb. Ordinates indicate molecular sizes in kDa of marker proteins. All blots are repre-
sentative of at least three independent experiments.
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Parafﬁn-embedded sections of human tissues were deparafﬁnized,
rehydrated, and immersed in 0.3% hydrogen peroxidase-containing
methanol for 20min at room temperature to inactivate the intrinsic per-
oxidase. After microwave treatment for antigen retrieval for 15 min in
10 mM sodium citrate buffer (pH 6.0), the sections were incubated
with each mAb at 4 °C overnight. After washing with PBS three times,
peroxidase-labeled goat anti-mouse IgG (Fab′) (Histoﬁne simple stain
MAX-PO (MULTI) kit; Nichirei Corp., Cat# 424152) was used as a
secondary Ab and was applied for 30 min at room temperature.
After washing with PBS three times, peroxidase was visualized with
3,3′-diaminobenzidine, using the Histoﬁne DAB substrate kit (Nichirei
Corp., Cat# 425011). The slides were then counterstained with Mayer's
hematoxylin solution (Wako, Cat# 131-09665). Images were obtained
using an optical microscope PROVIS AX-80 equipped with a DP70
camera and DP manager software (Olympus) or a NanoZoomer 2.0-RS
(Hamamatsu). For immunoﬂuorescent staining, Alexa Fluor 488-
conjugated anti-rabbit IgG and Alexa Fluor 546-conjugated anti-
mouse IgG were used as secondary Abs. Coverslips were mounted
using Fluorescent mounting medium (Dako). Fluorescence images
were obtained using an IX71 ﬂuorescent microscope (use of LUCPlan-
FLN 20×/0.45 objective) connected to a DP70 camera equipped with
DP manager software (Olympus).2.8. Cell culture
THP-1 is a human monocytic cell line derived from an acute mono-
cytic leukemia patient. It can be differentiated into macrophage-like
cells by PMA. THP-1 cell lines were cultured in RPMI 1640 medium(Wako, Cat# 168-23191) supplemented with 10% FBS (Nichirei Corp.)
and penicillin and streptomycin (Wako, Cat# 189-02025).
2.9. Preparation of cell lysates
The cell lysates were prepared in the following manner. The cells
were washed two times with cold PBS and then lysed with lysis buffer
(1% Triton X-100, 20 mM Tris–HCl (pH 7.4), 150 mM NaCl, and 5 mM
EDTA) containing a protease inhibitor cocktail (Nacalai Tesque,
Japan, Cat# 07575) and a phosphatase inhibitor cocktail (Roche, Cat#
4906845). After incubation for 10 min on ice, the cell lysates were clar-
iﬁed by centrifugation at 20,400 g for 10 min at 4 °C. The resultant su-
pernatant was used in the following experiments. The protein
concentrationwas determined using a protein assay kit (Nacalai Tesque.
Japan, Cat# 29449-44).
2.10. Migration assay
Cellmigrationwas assayed using a 24-well chemotaxis chamber (BD
Falcon cell culture companion plates Cat# 353504 and 8.0-μm inserts
Cat# 353097; BD Biosciences). THP-1 cells were treated for 48 h with
PMA (Wako, Cat# 1544-5) at 50 ng/ml to trigger differentiation of the
THP-1 cells into macrophages. Two hundred microliters of 1 × 106
cells/ml PMA-treated THP-1 cells (2 × 105 cells in 0.1% BSA containing
serum-free RPMI 1640 medium) were inoculated into each upper well
of a chamber, and 800 μl of 0.1% BSA containing serum-free RPMImedi-
umwith 120 μl of diluted sample by PBS (total 920 μl)were added to the
lower well of a chamber. After 15 h incubation, the cells on the upper
side of a membrane were removed with a cotton swab, and the cells
on the lower side of a membrane were ﬁxed with 5% glutaraldehyde
and stained with 0.5% crystal violet in 20% methanol. Random ﬁelds
Fig. 2.OPN expression in the cerebral cortex of NMOpatients. (A) HighOPN expression level in thewhitematter of NMO patients. Scale bar: 2.5mm.OPN expression around the boundary
area betweenwhite and graymatter in thepatientwith NMO(B),MS (C), andAD (D). Scale bars: 200 μm. The dashed lines indicate the boundary betweenwhite and graymatter. w,white
matter; g, graymatter. OPN expression in astrocytes (E; arrows), neurons (E;white arrowheads), and oligodendroglias (F; arrowheads) of the cerebral sections ofNMOpatients. Scale bars:
50 μm. (G andH) Serial cerebral section fromNMOpatients demonstrating perivascular inﬁltration of numerousmacrophages expressing OPN. The area in the rectangle in (G) is shown at
highermagniﬁcation in (H). The arrowheads in (H) indicate macrophages. Scale bars: 200 μm(G), and 50 μm(H). OPN stainingwas performed usingmAb against OPN (clone 53) on par-
afﬁn-embedded sections (n = 3) from two patients per disease. Photos in (B–H) are immunoperoxidase-stained with 3,3′-diaminobenzidine and hematoxylin counterstain. (I and
J) Representative immunoﬂuorescence staining of cerebral sections of anNMOpatient. (I) Stainingwith OPN (green) andGFAP (red: astrocytes). (J) Stainingwith OPN (green) andCNPase
(red: oligodendroglias). Nuclei were stained blue with Hoechst 33342. Scale bars: 50 μm.
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cells were photographed per condition. Then the numbers of migrated
cells were counted. For inhibition assays, cell suspensionswere incubat-
ed with function-blocking Abs, control IgG, or inhibitors for 20 min at
room temperature before inoculation.
2.11. Flow cytometric analysis
Cells were detached from a 10-cm dish using trypsin containing
1 mM EDTA. After quenching trypsinization with a medium containing
10% FBS, the cells were washed two times with PBS containing 1 mM
EDTA and incubated with primary Ab or control IgG on ice for 30 min.
The cells were washed three times with PBS that contained 1 mM
EDTA, followed by incubation for 15 min with the appropriate Alexa
Fluor-conjugated secondary Ab. After washing three times with PBS
that contained 1 mM EDTA, the cells were analyzed by ﬂow cytometry
using FACSCalibur and CellQuest software (BD Biosciences).
2.12. Statistical analysis
OPN levels and increased cell signaling were compared between
groups using the Kruskal–Wallis test followed by Dunn's post-test,with GraphPad Prism Version 5.0a software (GraphPad Software, Inc.).
Comparisons between two groups were made using Student's t-test
(two-tailed) and among groups using one-way ANOVA followed by a
Bonferroni post-test, with GraphPad Prism Version 5.0a software. A P
value of 0.05 was considered the threshold for statistical signiﬁcance.
3. Results
3.1. Increased OPN levels in NMO CSF
OPN is known to behave as an inﬂammatory cytokine, a fact consid-
ered relevant in MS [6]. To investigate any differences in OPN levels in
CSF between NMO and MS, we measured the levels in patients with
anti-AQP4 Ab-positive NMO (all at the relapse phase) and with MS
(all at the relapse phase), as well as in patients with other diseases
(control group). Western blot with 1 μl of CSF and anti-human OPN
pAb (clone O-17) revealed that OPN levels were elevated in CSF of
the patients with NMO relative to those with MS and with other
diseases, including sacroiliac joint dysfunction and Parkinson's
disease (Fig. 1A). Similar results arose from Western blot analysis
using the same quantity of CSF protein (3 μg) and anti-human OPN
pAb (Fig. 1B). To conﬁrm the results of Western blot analyses, we
Fig. 3. Dephosphorylation analysis of OPN in the CSF and serum of NMO patient. Dena-
tured 6 μl of CSF and 1 μl of serum samples from the same NMO patient were treated
with (+) or without (−) CIAP. After incubation for 1 h at 37 °C, samples were applied
to SDS-PAGE under reducing conditions, followed by Western blot using anti-human
OPN pAb. Black arrowheads indicate the band of phosphorylated OPN. White arrowhead
indicates the band of dephosphorylated OPN. Asterisk indicates the cleaved or degraded
forms of OPN. Note that OPN in the CSF was reduced in size after CIAP treatment but
OPN in the serummaintained almost identical size with andwithout CIAP treatment, sug-
gesting that CSF contains themore phosphorylated form of OPN than serum. Ordinates in-
dicate molecular sizes in kDa of marker proteins. Blots are representative of at least three
independent experiments.
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with NMO showed high OPN levels in their CSF, ranging from 512
to 3079 ng/ml (n = 19). In contrast, the patients with MS (n = 19)
and other diseases (n = 14) including sacroiliac joint dysfunction
(n = 1), Parkinson's disease (n = 1), cervical spondylosis (n = 1),
spinocerebellar ataxia type 6 (n = 1), multiple system atrophy-P
(n = 1), sarcoidosis (n = 1), HTLV-1-associated myelopathy (n = 1),
subterranean clover stunt disease (n = 1), and NMDAR Ab-negative
(n = 3) and -positive (n = 3) limbic encephalitis patients, had low
OPN levels, ranging from 94 to 203 ng/ml and from 89 to 210 ng/ml, re-
spectively. Because high OPN levels have been reported in both the
serum and plasma in MS [21,25], we compared these levels in NMO
and MS patients. We found no difference in OPN levels between the
two groups in the serum (Fig. 1D) or plasma (data not shown).Instead, a higher OPN level in NMO CSF than in MS CSF suggested that
OPN in CSF could be a biomarker to discriminate NMO from MS.
3.2. Pathological analyses of OPN in NMO
The results in Fig. 1 suggest that the cellular source of OPN in CSF
might be independent of that of OPN in the serum because the OPN
expression pattern in CSF was not relevant to the pattern in the
serum. To conﬁrm the possibility, we investigated the cellular expres-
sion patterns of OPN in human NMO brain sections by immunohisto-
chemistry. Immunostaining using mAb speciﬁcally recognizing OPN
(clone 53) showed that OPN was highly expressed in the white matter
of the cerebrum of the NMO patients whereas OPN was weakly
expressed in the gray matter (Fig. 2A). In the cerebrum of the patients
with MS (Fig. 2B), the OPN signal was quite low compared with that
in patients with NMO (Fig. 2C), whereas in the cerebrum of the patients
with AD, the OPN signal was almost undetectable (Fig. 2D). In the brain
of the patients with NMO, OPN was detected on astrocytes, which are
abundant in gray matter and have many ﬁne processes (Fig. 2E; ar-
rows), on neurons, which have a large cell body and large bright nucleus
(Fig. 2E; white arrowheads), and on oligodendrocytes, which are abun-
dant in white matter and have several processes (Fig. 2F; arrowheads).
OPN was highly expressed on perivascular inﬁltration of numerous
macrophages in the serial cerebral section from NMO patients (Fig. 2G
and H). Similar result was obtained using another anti-OPN mAb
(clone 10A16) (data not shown). The expression of OPN on astrocytes
and on oligodendrocytes was also conﬁrmed by double-
immunoﬂuorescent staining for OPN and cell type-speciﬁc marker pro-
teins (Fig. 2I and J). These results suggested that OPN expression was
highly upregulated in the NMO brain but not in the MS brain, which
was consistent with the results in Fig. 1.
OPN is a multiphosphorylated extracellular glycoprotein and the
molecular weight could be affected by phosphorylation [14]. The extent
of OPN phosphorylation is variable, and it depends on the cellular
source of OPN [15]. To further study the possibility that the cellular
source of OPN in CSF is different from that in the serum, we investigated
the OPN phosphorylation level in the CSF and serum of NMO patient
using alkaline phosphatase, CIAP (Fig. 3). Since dephosphorylated OPN
migrated faster than the phosphorylated OPN on SDS-PAGE gel [14],
we can determine phosphorylation levels of OPN by checking the
bandmobility before and after CIAP treatment. After dephosphorylation
with CIAP treatment, OPN was checked by Western blot using anti-
human OPN pAb (O-17). The 70–75 kDa bands of CSF OPN without
CIAP treatment completely disappeared after CIAP treatment and
bands around 55 kDa appeared after CIAP treatment, indicative of phos-
phorylated and nonphosphorylated forms of CSF OPN, respectively. On
the other hand, it was difﬁcult to detect any changes in serum OPN
band mobility. These results indicated that OPN in the CSF was more
phosphorylated than OPN in the serum, and that OPN in CSF and the
serum might be produced by different cellular sources.
3.3. OPN in NMO CSF promotes macrophage chemotaxis
OPN plays a role as a chemotactic cytokine for macrophages, den-
dritic cells and neutrophils in the inﬂammatory region [3,9], and exten-
sive macrophage inﬁltration was observed in demyelinated active
lesions of NMO patients [10,18]. In the present study, high OPN expres-
sion was observed in the NMO CSF (Fig. 1) and brain (Fig. 2). To investi-
gate whether OPN in NMO CSF might promote macrophage inﬁltration,
we performed a chemotaxis assay using human macrophage-like cells,
THP-1 cell lines, and the CSF samples from NMO patients. Compared
to the control PBS, 10 μl of NMO CSF including 25 ng OPN signiﬁcantly
increased themigration of THP-1 cellswhereas 10 μl ofMS CSF including
1.2 ng OPN slightly induced the chemotactic migration of THP-1 cells
(Fig. 4A). NMO CSF, but not MS CSF, caused the chemotactic migration
of THP-1 cells in a dose-dependent manner (Fig. 4B). Surprisingly,
Fig. 4. In vitro chemotaxis assay using NMO andMS CSF. In vitro chemotaxis assay using CSF of NMO (OPN concentration, 859 ng/ml) or MS patients (OPN concentration, 125 ng/ml). The
volume of CSF samples was adjusted to be 120 μl with PBS. The 120 μl of sample or control PBS was added to 800 μl of 0.1% BSA containing serum-free medium in the lower well of the
chamber. Themigrated cells on the lower side of amembranewere photographed using a phase contrastmicroscope (A), and theywere counted (B). Numerical values on the longitudinal
axis indicate the ﬁnal concentration of OPN in the lower chamber (ng/ml). We used a one-way ANOVA followed by a Bonferroni post-test to assess differences. **p b 0.01 vs. 2.3 ng/ml
NMO, ***p b 0.001 vs. 2.3 ng/ml NMO. (C) Cells were pretreated with a control mouse IgG (IgG) or mouse anti-OPN mAb (OPN mAb) and plated on the upper chamber in the presence
of NMOCSF (OPN concentration in the lower chamber: 9.3 ng/ml) orMS CSF (OPN concentration in the lower chamber: 4.1 ng/ml) in the lower chamber. The relative number of migrated
cells to the lower surface of themembrane in the presence ofmouse IgGwas taken as 100%.We used a two-tailed Student's t-test to assess differences. Data are represented as themean±
SD from three independent experiments with at least triplicate data points per experiment. Other experimental conditions are described in the Materials and methods section.
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was higher than that in the NMO CSF-containing chamber, MS CSF-
induced chemotaxiswas still weaker thanNMOCSF-induced chemotax-
is (Fig. 4B, NMO 2.3 ng/ml vsMS 2.7, 4.1, 8.2, 16.3 ng/ml). To investigate
whether OPN in NMO CSF directly affected such chemotactic migration
of THP-1 cells, we examined the inhibitory effect of anti-OPN mAb
(clone 53) that blocks OPN function in chemotactic activity. TheFig. 5. OPN in NMO CSF promotes macrophagemotility through integrin αvβ3. (A) Expression
analysis. Prior to analysis, the cells were incubated with either the indicated Abs or control IgG
terials and Methods. Inhibitory effect of 20 μg/ml integrin αvβ3 mAb (clone LM609, B), 100
MS CSF-induced cell motility. The relative number of migrated cells to the lower surface of them
peptide (RGE, C) was taken as 100%. We used a two-tailed Student's t-test to assess difference
points per experiment. Other experimental conditions are described in the Materials and methneutralizing mAb of OPN markedly abrogated NMO CSF-induced che-
motaxis but had no inhibitory effect on MS CSF-induced chemotaxis
(Fig. 4C). These results indicated that OPN in NMO CSF induced macro-
phage chemotaxis, whereas OPN in MS CSF might have no ability to in-
duce it.
OPN often uses integrin αvβ3 and CD44 as a cell surface receptor,
and the association of OPN with them stimulates cellular signaling,levels of integrinαvβ3 and CD44 on the surface of THP-1 cells were examined using FACS
, followed by incubation with Alexa Fluor-conjugated secondary Abs, as described in Ma-
μM GRGDSP peptide (RGD, C), and 20 μg/ml CD44 mAb (clone Hermes-1, D) on NMO or
embrane in the presence of 20 μg/ml control IgG (IgG, B andD) or 100 μMcontrol GRGESP
s. Data are means ± SDs from two or three independent experiments with triplicate data
ods section.
Fig. 6. Cell signaling pathways for NMO CSF-induced cell motility. (A) Effects of various cellular signaling inhibitors on NMO CSF-induced cell motility. THP-1 cells were pretreated with
PBS, DMSO, and the indicated inhibitors for 20 min at room temperature and plated on the upper chamber in the presence of NMO CSF in the lower chamber: PI3K inhibitor LY294002
(25 μM), MEK1/2 inhibitor U0126 (20 μM), JNK inhibitor SP600125 (100 μM), and p38MAPK inhibitor SB203580 (20 μM). DMSO was used as a solvent. Data are means ± SDs from
two independent experiments with triplicate data points per experiment (one-way ANOVA, Bonferroni post-test). ***p b 0.001 vs. DMSO. NS, not signiﬁcant. The data were derived by
subtracting the numbers of migrated cells in the control (PBS) from those in each condition. (B) PMA-treated THP-1 cells in serum-free medium were cultured in the presence of PBS
(None) andCSF ofNMOpatients (NMO) and ofMSpatients (MS). After 1 h incubation, cell lysateswere collected and immunoblotted against the indicatedAbs. All blots are representative
of at least three independent experiments. (C) Results of the densitometric analysis are shown as the integrated density of the ratio of phosphorylated protein to total protein bands in
Fig. 6B (Kruskal–Wallis test, Dunn's post-test.), which was 1.0 for PBS-treated cells (None). *p b 0.05. **p b 0.01. NS, not signiﬁcant. (D) Effect of functional blocking mAb against OPN
(clone 53) on the increased cell signaling by NMO CSF. PBS and NMO CSF were pretreated with either control mouse IgG or functional blocking mAb against OPN (NMO/Ab) for
15 min at room temperature. Other experimental conditions are described in Fig. 6B. Results of the densitometric analysis are shown as the integrated density of the ratio of phosphor-
ylated protein to total protein bands. *p b 0.05. **p b 0.01. ***p b 0.001.
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gration. FACS analysis revealed that after differentiation by PMA,
macrophage-like THP-1 cells expressed both integrin αvβ3 and CD44
on their cell surfaces (Fig. 5A). To clarify which receptors were mainly
used in NMO CSF-induced chemotaxis, which was primarily attributed
to OPN, we performed inhibitory assays using mAbs against integrin
αvβ3 (clone LM609) and CD44 (clone Hermes-1). NMO CSF-induced
chemotaxis was decreased by 50% in the presence of the neutralizing
mAb against integrinαvβ3 (Fig. 5B). RGD sequence-containing peptide,
GRGDSP, is a competitor of RGD-recognizing integrin including integrin
αvβ3. Similar results were obtained when the GRGDSP peptide, but not
the control Arg–Gly–Glu (RGE) sequence-containing peptide, GRGESP,
was used instead of the neutralizing mAb against integrin αvβ3 in a
chemotaxis inhibition assay (Fig. 5C). In contrast, the neutralizing
mAb against CD44 had no effect on NMO CSF-induced chemotaxis
(Fig. 5D) although the mAb blocked the chemotaxis of MDA-MB231
cells to about 30% (Fig. S1). These results suggested that OPN in NMO
CSFmainly used integrinαvβ3, but not CD44, as a receptor to cause che-
motactic activity. However, the results that neither integrin αvβ3 and
CD44 mAbs nor the RGD peptide suppressed MS CSF-induced chemo-
taxis (Fig. 5B–D, MS) were in accordance with the result that OPN
function-blockingmAb had no inhibitory effect onMS CSF-induced che-
motaxis (Fig. 4C).
3.4. Analysis of OPN-activated signaling pathways
To analyze the signaling pathways that OPN in NMO CSF used to in-
duce chemotaxis, we examined the effect of various signaling inhibitors
on NMO CSF-induced chemotaxis (Fig. 6A). Compared to the solvent(DMSO) as a control, the chemotactic ability of NMO CSF was markedly
reduced by the treatment of cells with the PI3K inhibitor LY294002 or
the MEK1/2 inhibitor U0126. In contrast, the JNK inhibitor SP600125
and the p38MAPK inhibitor SB203580 had almost no inhibitory effect
on NMO CSF-induced chemotaxis. To conﬁrm the results obtained
using these inhibitors, we investigated the phosphorylation state of
Akt (downstream of PI3K), MEK1/2, JNK, and p38MAPK in THP-1 cells
in the absence (None) or presence of NMO and MS CSF (Fig. 6B). NMO
CSF, but not MS CSF, signiﬁcantly promoted Akt and ERK1/2 phosphor-
ylation but not JNK and p38MAPK phosphorylation compared to the
control (Fig. 6B and C), and the Akt and ERK1/2 signaling activations
by NMO CSF were reversed with functional blocking mAb against OPN
(Fig. 6D), suggesting that OPN in NMO CSF induced the activation of
PI3K and MEK1/2, but not of JNK and p38MAPK, signaling pathways.
These results indicated that NMO CSF-induced chemotaxis, which was
mainly attributed to OPN activity, was mediated by PI3K and MEK1/2,
but not by JNK and p38MAPK, signaling cascades.
4. Discussion
For selecting appropriate treatment, it is crucial to distinguish the
two disorders, NMO andMS. In this study, we identiﬁed OPN as a possi-
ble biomarker for NMO. Although AQP4 Ab is a speciﬁc biomarker for
NMO, anAQP4 Ab assay is required for a high sensitivity cell culture sys-
tem. Therefore, the AQP4 Ab assay can only be performed in a limited
number of institutions. In contrast, OPN can be effectively detected
using simple techniques such as Western blot and ELISA, which are a
major advantage over the existing methods to detect AQP4 Abs. Thus,
the OPN assays could support NMO diagnosis using the AQP4 Ab assay.
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poorly understood. Recent reports indicate that NMO-IgG may not
be a primary factor for NMO onset because of a report about a patient
with NMO who had NMO-IgG years before being symptomatic [20].
This suggests that NMO-IgG by itself cannot induce inﬂammation;
instead, disease onset of NMO and associated inﬂammatory lesions
are required before astrocytes are attacked by NMO-IgG, the anti-
AQP4 Ab. The present study showed that in vivo, OPN in NMO CSF
was upregulated, and in an in vitro assay, it promoted macrophage
motility, which was associated with inﬂammatory disease. In addi-
tion, remarkable vascular inﬂammatory inﬁltration of macrophages
accompanied by astrocyte loss was observed in the brains of NMO
patients (data not shown). Because OPN is known to work as an in-
ﬂammatory cytokine in some inﬂammatory diseases and cancer as
well as autoimmune disease, OPN may participate in NMO disease
onset and in NMO disease progression or both. This will be further
addressed in future studies using animal models.
NMO CSF contained a signiﬁcant amount of OPN and strongly pro-
moted THP-1 motility in an OPN dose-dependent manner. In Fig. 4C,
however, neutralizing mAb against OPN did not completely abolish
NMO CSF-induced chemotaxis. In contrast, MS CSF induced weak cell
motility in an OPN-independent manner. Therefore, not only OPN but
also cytokines and other proteins may participate in NMO and MS
CSF-induced chemotaxis.
IL-17-producing CD4+ T helper (Th17) cells have recently been
identiﬁed as a new effector T cell subset involved in the pathogenesis
of autoimmune diseases, including rheumatoid arthritis and MS. OPN
induces IL-17 production by CD4+ T cells through the integrin αvβ3
[19]. Treatment using anti-integrin αvβ3 Ab and anti-OPN Ab reduced
the clinical severity of EAE by reducing IL-17 production [19]. Recent
studies using the EAE mouse model indicated that the IFN-β treatment
signiﬁcantly attenuated the progression of EAE symptoms in Th1-
induced EAE but exacerbated the disease in Th17-induced EAE [2].
Levels of IL-17, which is secreted from Th17 cells, were signiﬁcantly
elevated in CSF of NMO patients compared withMS patients [11]. In ad-
dition, OPN is also secreted from Th17 cells and appears to play a critical
role in Th17 differentiation [7]. Thus, elevated OPN levels in NMOmight
promote Th differentiation to Th17. Considering that the IFN-β treat-
ment induces severe relapses and exacerbations in NMO, the immune
response in NMO might mainly be mediated by Th17 cells rather than
Th1 cells.
Dephosphorylation with CIAP decreased the molecular size of OPN
inNMOCSF but had no effect on the size of OPN inNMO serum, suggest-
ing that OPN in CSF was a more phosphorylated form than that in the
serum (Fig. 3). The interaction of OPN with cell surface receptors is de-
termined by its phosphorylation state. Therefore, OPN in CSF could be
associated with cell surface receptors distinct from OPN in the serum.
The discovery of differences in OPN phosphorylation levels between
CSF and the serum among NMO patients might indicate that OPN in
the serum does not penetrate CNS blood–brain barrier. The present
study demonstrated that OPN in NMO CNSwas produced by astrocytes,
neurons, oligodendroglias, and macrophages (Figs. 2E–J). Therefore,
OPN in CSF of NMO patients could be derived from neural cells and in-
ﬁltrating immune cells in CNS of the patients but not from their serum.
Recent studies have reported that the genetic deﬁciency of a
tartrate-resistant form of acid phosphatase (TRAP), which is expressed
in bone and in immune cells and can be actively secreted, is associated
with skeletal dysplasia and cerebral calciﬁcations as well as autoimmu-
nity [5,16]. Because OPN is known to be a dephosphorylated protein by
TRAP, TRAPmight regulate OPN functions by controlling its phosphory-
lation status. In this study, OPN in NMO, but not MS, CSF dose depen-
dently induced cell motility by activating signaling pathways through
PI3K and MEK1/2 but not JNK and p38MAPK. Although speculative,
the idea that speciﬁc phosphorylation sites in the OPN molecules
could induce the activation of PI3K and MEK1/2 signaling pathways
might explain the different active states between the two disorders.Further studies such as the identiﬁcation of the phosphorylation sites
in OPN from NMO and MS CSF are required to address the question
why OPN in MS CSF could not efﬁciently promote THP-1 cell motility
in the chemotaxis assay.
In conclusion, our ﬁndings provide a rationale to target OPN as a bio-
marker and a potential therapeutic approach in NMO diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2015.01.003.
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